Revolutionary RNA-ISH Technology Partnership Between Leaders
Leica Biosystems Forms Strategic Alliance with Molecular Instruments
Leica Biosystems, a renowned player in cancer diagnostics known for its robust workflow solutions, has announced a groundbreaking partnership with Molecular Instruments, the innovative minds behind the HCR™ Imaging technology. This collaboration aims to significantly advance the capabilities in RNA in situ hybridization (RNA-ISH) by leveraging fully integrated systems utilizing the BOND RX and BOND RXm research staining instruments.
Enhanced RNA and Protein Detection Capabilities
This strategic alliance marks the beginning of a promising collaboration between these two industry leaders. By integrating HCR™ Pro RNA-ISH technology with existing protocols for immunohistochemistry and immunofluorescence, researchers can now simultaneously detect RNA and protein targets from a single tissue sample. This dual functionality not only maximizes the information extracted from samples but also ensures valuable tissue samples are preserved for future analysis.
Benefits of the HCR™ Pro RNA-ISH Technology
The introduction of HCR™ Pro RNA-ISH to the BOND RX and RXm systems is particularly exciting. According to Dr. Aneesh Acharya, Chief Commercial Officer of Molecular Instruments, the adoption of HCR™ Pro kits has seen impressive momentum. Users have quickly appreciated its capabilities, and the collaboration with Leica Biosystems is poised to enhance this transition from traditional methods to innovative RNA-ISH techniques.
Transforming Cancer Research
This advanced RNA-ISH technology is pivotal for both brightfield and fluorescent imaging, enabling scientists to target any RNA in formalin-fixed, paraffin-embedded tissue samples efficiently. Designed for speed and versatility, HCR™ Pro utilizes a powerful signal amplification platform that has been successfully employed in various applications for over ten years. The synergy between this innovative technology and the BOND systems is expected to catalyze a new frontier in RNA research, enhancing overall capabilities.
Advancements in Research Staining Automation
Karan Arora, Senior Vice President at Leica Biosystems, expressed enthusiasm about this new addition to their portfolio, stating that it strongly positions BOND RX as a leader in research staining automation. The partnership with Molecular Instruments represents a critical advancement in making pioneering technology accessible to the scientific community, catering specifically to cancer research. Through this collaboration, researchers are equipped with the tools necessary to unlock profound insights into RNA expression and enhance understanding of cancer biology.
Commitment to Quality and Innovation
Both companies share a commitment to quality, efficiency, and transformative innovation in diagnostics. Molecular Instruments offers a comprehensive suite of kits powered by its HCR™ platform for various imaging applications, making them invaluable for academic research and clinical pathology. Through improving accessibility and offering resources like starter kits and custom probe designs, they ensure that researchers can easily engage with these technologies.
About Molecular Instruments
Molecular Instruments specializes in developing and synthesizing state-of-the-art kits for bioimaging applications, further bridging the gap between complex methodologies and practical use in research. Their innovative HCR™ platform is designed with efficiency and effectiveness in mind, ensuring that researchers have the capabilities to explore and document findings with ease.
About Leica Biosystems
Leica Biosystems stands at the forefront of cancer diagnostics, delivering a broad range of solutions from biopsy to diagnosis. They are dedicated to facilitating communication among healthcare providers across multiple disciplines, including radiology and oncology. Their mission, “Advancing Cancer Diagnostics, Improving Lives,” reflects their commitment to pushing the boundaries of diagnostic capabilities while enhancing patient care.
Frequently Asked Questions
What is the partnership between Leica Biosystems and Molecular Instruments about?
The partnership aims to integrate HCR™ Pro RNA-ISH technology into Leica Biosystems' BOND RX and BOND RXm research staining systems, enhancing cancer diagnostics.
How does the HCR™ Pro RNA-ISH technology work?
This technology allows simultaneous detection of RNA and protein in tissue samples, maximizing information extraction while preserving tissue for further research.
Why is this technology important for researchers?
It enables researchers to gather deeper insights into RNA expression and cancer biology, crucial for advancing knowledge and treatments.
What are the advantages of using BOND RX systems?
BOND RX systems provide automation and efficiency in research, allowing for consistent and reliable results across a variety of staining applications.
Can this technology be used in hospital diagnostics?
The HCR™ Pro RNA-ISH is intended for research use only and not for diagnostic procedures, focusing instead on advanced research and development purposes.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.
